Goldman Sachs resumed coverage of Altimmune (ALT) with a Sell rating and $1 price target representing 79% downside. The company’s data to-date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or metabolic dysfunction associated steatohepatitis, the analyst tells investors in a research note. The firm sees challenges for Altimmune to execute the full clinical development program required to bring pemvidutide to market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development
- Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
- Altimmune enrolls first patient in Restore Phase 2 trial
- Altimmune’s Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential
- Optimistic Outlook for Altimmune’s Pemvidutide Despite Phase 2b Setback